NCT03728972 - Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

June 15, 2025

Study Completion Date

November 30, 2026

Conditions

NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

Interventions

DRUG

Pembrolizumab

200mg IVPB every 3 weeks

Trial Locations (10)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack

Md Anderson Cancer Center, Houston

Stanford University, Stanford

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

Hackensack Meridian Health, Hackensack

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER